Hematology/Oncology

Top Story

Regen developing new gene procedure for targeting liver cancer cells

August 31, 2015

Regen BioPharma, Inc. announced it is currently developing a gene delivery procedure that will enable RGBP-248, a gene silencing nucleic acid, to reach liver tumors and cancerous cells in the body faster and, in turn, treat unresectable liver cancer, according to a press release.

According to the release, the product is still in development and this type of local delivery system will allow for reduced amounts of potential toxicities and enable a higher amount of the therapeutic product to reach the tumor for treatment.

Gregory Masters In the Journals

ASCO updates guideline on treatment of advanced NSCLC

August 31, 2015
ASCO has updated its clinical practice guideline on systemic therapy for stage IV non–small cell lung cancer.The evidence-based recommendations provide guidance on…

Patients with RA may be at greater risk for developing lung cancer, lymphoma

August 31, 2015
Patients with rheumatoid arthritis may have a higher risk for developing lung cancer or lymphoma compared with the general population but may be at lower risk for…
FDA News

FDA grants priority review to MCNA for nonmuscle-invasive bladder cancer

August 31, 2015
The FDA granted priority review to MCNA for patients with high-risk nonmuscle-invasive bladder cancer, according to a press release from the drug’s…
David M. Gershenson, MD In the Journals

Younger age predicts worse survival from low-grade serous carcinoma of ovary, peritoneum

August 31, 2015
Women aged 35 or younger with low-grade serous carcinoma of the ovary or the peritoneum, as well as those with persistent disease upon therapy completion, have worse…
More News Headlines »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
morganatic-roan